April 30, 2013 –   The U.S. Food and Drug Administration (FDA) has determined that the drug Tolvaptan (Samsca) should not be used for longer than 30 days and should not be used in patients with underlying liver disease because it can …

FDA limits duration and usage of Tolvaptan (Samsca) due to possible liver injury leading to organ transplant or death Read more »